Clinical Asthma Phenotypes and Therapeutic Responses

Table 3

Effect of montelukast versus fluticasone on pulmonary function and airway inflammatory biomarkers in cough phenotype group (G2).

	G2A			G2B			𝑃
	Before treatment	After treatment	Percentage change	Before treatment	After treatment	Percentage change
FEV1; % predicted	66.3±2.1	79.2±2.2 *	19.46%	67.9±2.4	69.2±0.8	1.9%	0.6
Total sIgE (IU/mL)	134.2±32.1	130.1±29.7	−3.05%	130.6±28.2	125.8±20.9	−3.67%	0.82
Peripheral eosinophilic%	8.31±0.29	4.3±0.1 *	−48.2%	7.6±0.71	6.2±0.3	−18.4%	0.52
sECP; (𝜇g/L)	76.22±9.8	44.9±3.2 *	−41.09%	72.9±1.2	68.3±2.3	−6.3%	0.56
sICAM-1; (ng/mL)	713.2±69.2	698.2±53.2	−2.1%	709.8±71.2	698.2±66.2	−1.63%	0.67
sVCAM-1; (ng/mL)	850.3±219.8	832.2±188.9	−2.13%	844.3±211.2	813.2±189.3	−3.68%	0.78
sIL-2R; (pg/mL)	3461±488.2	3319±378.2	−4.1%	3453.1±399.2	3402.2±298.8	−1.47%	0.46

G2A: cough group treated with montelukast. G2B: cough group treated with fluticasone.
Data are expressed as mean (SD). *𝑃<0.05 is significant (for each group before and after treatment).
Mann-Whitney 𝑈-test was used to compare both groups.